Valeant names slate to support its bid for Cephalon
Monday, April 11th, 2011 at
1:07 am
Valeant names slate to support its bid for Cephalon
After its offer to buy Frazer biopharmaceutical company Cephalon Inc. for $ 5.7 billion was rejected late Tuesday, Valeant Pharmaceuticals International Inc. nominated its own slate of seven directors to replace Cephalon's board.
Read more on Philly.com
![]() |





US $5.95







Leave a Reply